S uperoxide anion (O 2
Ϫ ) can interfere with nitric oxide (NO)-dependent vasodilatation [1] [2] [3] [4] and participate in endothelium-dependent constriction. 5, 6 O 2 Ϫ has also been shown to affect the sensitivity of blood vessels to vasodilators. 7 Numerous reports demonstrate that superoxide dismutase (SOD) can improve relaxation of blood vessels. 1, 3, 4 We and others have suggested that NAD(P)H oxidase-derived O 2 Ϫ inhibits NO-dependent relaxation, 8 -10 and NAD(P)H oxidase-derived O 2 Ϫ has been implicated in angiotensin (Ang) II-induced blood pressure elevation. 8, 11, 12 A number of studies have shown that a phagocyte-like NAD(P)H oxidase is the major source of O 2 Ϫ in vascular tissue. 8, 13, 14 Recent studies show that Ang II increases mRNA levels of p22 phox and p67 phox 15, 16 and can also stimulate NAD(P)H oxidase O 2 Ϫ production by neutrophils 17 as well as by the vascular endothelium, medial smooth muscle cells, and adventitial fibroblasts. 9, 15, 16, 18, 19 It is well known that activation of NAD(P)H oxidase in neutrophils is triggered via protein kinase C (PKC)-mediated phosphorylation of cytosolic p47
phox , which then binds to membrane-associated gp91 phox . 20 Recently, a similar process has been inferred in the vasculature, since it was shown in a model of renovascular hypertension (2 kidneys, 1 clip) that calphostin C, an inhibitor of PKC, decreased O 2 Ϫ levels in aortas from hypertensive animals, 21 suggesting that the mechanism of activation is similar between neutrophil and vascular NAD(P)H oxidase. Moreover, p47
phox translocates to the membrane of endothelial and smooth muscle cells upon stimulation with phorbol esters and thrombin, respectively. [22] [23] [24] However, it is unclear whether gp91 phox , its smooth muscle homologue nox1-containing NAD(P)H oxidase, 25 or nox4 26, 27 mediates Ang II-dependent increases in O 2 Ϫ in the vasculature and participates in the development of hypertension.
Although there is evidence linking NAD(P)H oxidase and hypertension, there is a lack of effective inhibitors targeting this oxidase that do not inhibit other flavin-dependent enzymes. For this reason, we designed chimeric peptides that would interfere with the assembly of vascular NAD(P)H oxidase components. In human neutrophils, small peptide sequences of gp91 phox , which are involved in the binding of gp91 phox to p47 phox , inhibit O 2 Ϫ formation in cell-free assays. 28, 29 We selected the sequence found to be most potent in cell-free human neutrophil assays and then determined the corresponding sequence from the gp91 phox mouse clone, 30 calling it gp91ds (gp91 docking sequence). This represents a 1-amino acid difference between the human and mouse neutrophil sequence, a substitution of isoleucine for valine at amino acid 89. Using the LALIGN server, we recently found that homologous sequences exist in nox1 25 and nox4 26 that correspond to the site of p47 phox binding, and thus we expect the peptide to be useful in blocking the involvement of oxidases containing these homologues. Indeed, since previous reports show a functional requirement of p47 phox translocation to plasma membranes in smooth muscle cells, 24 which have been shown to contain primarily nox1 and nox4, 31 interaction of p47 phox with anchoring gp91 phox -like components appears to be fundamental to this family of enzymes. As we aimed to deliver this peptide either to the whole animal or intact vessels, we linked it to a specific 9-amino acid peptide of HIV viral coats (HIV-tat), which is known to be internalized by all cells 32 and was shown to deliver conjugated proteins after intravenous injection 33 (gp91ds-tat). As a control, we scrambled the 9-amino acid gp91
phox sequence in a way that generated the lowest number of hits when matched against the GenBank database and linked it to the 9-amino acid tat peptide in the same fashion (scramb-tat). In vitro, gp91ds-tat was found to be effective at blocking Ang IIinduced O 2 Ϫ levels in the mouse aorta. To test the efficacy of this NAD(P)H oxidase inhibitor in vivo, we coinfused the chimeric peptide with Ang II and examined its effects on blood pressure elevation and vascular O 2 Ϫ .
Materials and Methods
Lucigenin and diethyldithiocarbamate (DDC) (Sigma) were solubilized in physiological buffer; dimethylsulfoxide 4,5-dihydroxy-1,3-benzene disulfonic acid (Tiron; Sigma) was solubilized in H 2 O. Ang II was obtained from Sigma and diluted in 0.9% saline with 0.01 N acetic acid. Chimeric peptides (patent pending) were synthesized by the Protein Chemistry Facility of Tufts University (Boston, Mass) and diluted in solutions containing Ang II. The sequence of gp91ds-tat (patent pending) is as follows:
The sequence of scramb-tat (patent pending) is as follows:
Peptides were synthesized with an ABI 431A peptide synthesizer using FMOC amino acids and HTBU activator. The purity of these preparations was Ϸ70%, with the balance being deletions and chain terminations of the full-length peptide. Further attempts at purification using reverse-phase C18 column chromatography did not result in substantially greater purity of the peptide or biological activity and also decreased yield considerably.
Animals and Systolic Blood Pressure (SBP) Measurements
C57Bl/6Tac male mice 8 to 9 weeks old were purchased from Taconic Farms (Germantown, NY), and SBP was measured as described in the online data supplement. 
Surgery and Peptide Infusions

Ex Vivo Measurement of O 2
؊
Aortas from mice infused with Ang II, Ang IIϩgp91ds-tat, or Ang IIϩscramb-tat were cleaned of adipose tissue and cut into rings and incubated for 30 minutes in modified Krebs-HEPES buffer (pH 7.4) at 37°C in the presence of DDC (10 mmol/L) to inhibit endogenous Cu/Zn SOD as described previously. 12 Luminescence measurements were integrated for 30-second periods and the cycle repeated 9 times, then averaged. A standard curve was obtained as described previously 12 to express values in nmol O 2 Ϫ /min per mg of tissue.
Dihydroethidium (HE) Staining
HE was used to evaluate in situ production of superoxide. 34 Unfixed frozen ring segments from vehicle, Ang II, Ang IIϩgp91ds-tat, and Ang IIϩscramb-tat-treated mice were cut into 30-m-thick sections and placed on a glass slide. HE (2 mol/L) was topically applied to each tissue section. Images were obtained with a Bio-Rad MRC-1024 laser scanning confocal microscope.
NAD(P)H Oxidase Inhibition In Vitro
Aortas were removed, cleaned as described above, and preincubated for 30 minutes in Krebs-HEPES buffer with either gp91ds-tat (50 mol/L), tat, or vehicle at 37°C. Ang II (10 pmol/L) or vehicle was added and the tube incubated for 3 hours. The same procedures as for the ex vivo measurements were followed except that the lucigenin concentration was 25 mol/L.
NAD(P)H Oxidase Activity in Aortic Fibroblasts
We tested the capacity of gp91ds-tat to inhibit NADPH-dependent oxidase activity in membranes from cultured rat aortic adventitial fibroblasts. Cells were preincubated with vehicle or gp91ds-tat (30 minutes) and then with vehicle, Ang II (10 nmol/L), or Ang IIϩgp91ds-tat (50 mol/L) for 3 hours. Oxidase activity is expressed as a percentage relative to activity from vehicle-treated cells.
Effect of gp91ds-tat on Human Neutrophil O 2 ؊ Production
The effectiveness of gp91ds-tat to inhibit O 2 Ϫ production in intact neutrophils was measured using a standard cytochrome c-based assay as described previously. 35 
Tests of gp91ds-tat Specificity
To confirm the specificity of gp91ds-tat, we tested its effect on the potassium superoxide (KO 2 )-generated O 2 Ϫ . Formation of O 2 Ϫ anion by KO 2 was determined in the presence of vehicle or gp91ds-tat. We also tested the effect of gp91ds-tat on xanthine oxidase (XO)/ hypoxanthine-derived O 2 Ϫ . XO (0.1 U/mL) was incubated for 3 hours at room temperature with vehicle or gp91ds-tat (50 mol/L). Measurements were made using 5 mol/L lucigenin.
Statistical Analysis
Data are expressed as meanϮSEM, with n as the number of animals for each experiment. The significance of point differences in O 2 Ϫ generation in vitro was analyzed by Student's t test. Differences in SBP were analyzed by ANOVA followed by Holm's method for multiple comparisons. Differences in ex vivo O 2 Ϫ production were
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analyzed by ANOVA followed by Tukey's comparison. PϽ0.05 was considered significant. An expanded Materials and Methods section can be found in the online data supplement available at http://www.circresaha.org.
Results
In Vitro Measurements of O 2
؊
We first tested the ability of gp91ds-tat to inhibit vascular O 2 Ϫ in vitro. Ang II (10 pmol/L) increased aortic O 2 Ϫ 2.5-fold compared with vehicle control. Preincubation of aortic rings with gp91ds-tat (50 mol/L) for 30 minutes completely blocked Ang II-induced O 2 Ϫ production (nϭ8). In contrast, preincubation of rings for 30 minutes with tat alone did not inhibit Ang II-induced O 2 Ϫ , consistent with gp91ds-tat inhibiting aortic oxidase and O 2 Ϫ generation ( Figure 1 ). To confirm that gp91ds-tat was capable of inhibiting subcellular oxidase activity, quiescent rat aortic fibroblasts treated with Ang II demonstrated NAD(P)H oxidase activity that was 165Ϯ35% of vehicle control. This increase was substantially lower than we expected and previously reported for rabbit fibroblasts. Nonetheless, this activity was reduced to 80Ϯ19% of vehicle control activity by coincubation with gp91ds-tat (nϭ5).
We further examined the specificity of gp91ds-tat to inhibit NAD(P)H oxidase by two means. First, we examined whether gp91ds-tat could directly scavenge O 2 Ϫ produced by an inorganic source. KO 2 is known to react in aqueous solutions, releasing O 2 Ϫ . 36 Production of O 2 Ϫ by KO 2 was measured in the presence of vehicle, gp91ds-tat (50 mol/L), or SOD (150 U/mL). SOD significantly reduced O 2 Ϫ detection (nϭ5), but no effect was observed in the presence of gp91ds-tat (nϭ6) (Figure 2A) .
We also tested whether the chimeric peptide could inhibit another prevalent vascular enzymatic O 2 Ϫ source. XO (0.1 U/mL) was incubated for 3 hours at room temperature with vehicle or gp91ds-tat (50 mol/L). An aliquot of XO was added to tubes (dilution 1:50) containing lucigenin (5 mol/L) and gp91ds-tat (50 mol/L).
gp91ds-tat did not affect O 2
Ϫ production by XO (nϭ4) ( Figure 2B ), suggesting that gp91ds-tat is unable to directly inhibit this enzyme and corroborating its inability to directly scavenge O 2 Ϫ .
In Vivo Effects of gp91ds-tat
To test the ability of the inhibitors to decrease vascular O 2 Ϫ and blood pressure in vivo, we infused mice with Ang II in the presence and absence of gp91ds-tat or scramb-tat. As expected, Ang II infusion significantly increased total aortic 
O 2
Ϫ ex vivo compared with sham (nϭ6), and cotreatment with gp91ds-tat abolished the increase produced by Ang II (nϭ5). On the contrary, scramb-tat was ineffective at inhibiting Ang II-induced O 2 Ϫ formation (nϭ4) (Figure 3 ).
HE Staining
To further test the effect of gp91ds-tat on vascular cell O 2 Ϫ generation, HE was compared in aortas from the various treatment groups. Ang II treatment significantly increased the fluorescent signal in the three vascular layers compared with vehicle, indicative of an increase in O 2 Ϫ in all segments of the aorta. This increase was inhibited throughout the aorta by cotreatment with gp91ds-tat but not scramb-tat (Figure 4) .
Effect of gp91ds-tat on SBP
Ang II infusion (0.75 mg · kg Ϫ1 · d
Ϫ1
, IP) significantly increased SBP compared with vehicle ( Figure 5 ). Coinfusion with gp91ds-tat significantly attenuated SBP at all time points after implantation compared with Ang IIϩscramb-tat or Ang II alone ( Figures 5A and 5B, respectively) and reduced the increase caused by Ang II alone by 44% on day 
Effect of gp91ds-tat on O 2 ؊ Production by Neutrophils
We tested the ability of gp91ds-tat to inhibit O 2 Ϫ production in neutrophils on activation with phorbol myristate acetate (PMA). Although the gp91ds sequence blocked neutrophil O 2 Ϫ by 80% in a cell-free assay, 28 O 2 Ϫ production was reduced only by 35% when the highest concentration of gp91ds-tat (100 mol/L) was used in the cell-intact assay ( Figure 6A ; PϽ0.01; nϭ3). Scramb-tat did not significantly reduce neutrophil O 2 Ϫ production ( Figure 6B ).
Discussion
The results reported in the present study are evidence for direct involvement of NAD(P)H oxidases in Ang II-induced O 2 Ϫ and blood pressure elevation and provide a novel means of inhibiting NAD(P)H oxidase in whole-cell preparations and in vivo. Previous attempts at testing the contribution of NAD(P)H oxidase to increased O 2 Ϫ and blood pressure in vivo have been difficult because of the lack of specific and effective inhibitors of vascular NAD(P)H oxidases; for example, diphenylene iodonium, the classic inhibitor of NAD(P)H oxidase, also inhibits a variety of enzymes including XO 37 and NO synthases. 38 We previously detected phagocyte-like gp91 phox in aortas of rabbits 14, 39 and rats 10 and showed upregulation in response to Ang II in mice. 12 Others have demonstrated its homologues nox1 and nox4 in vascular cells 24 ; these appear to be related to gp91
phox at the N-terminal end, which contains regions that interact with p47
phox . Based on this knowledge, we developed a competitive antagonist of the interaction of gp91 phox and p47 phox and showed that it can suppress the induction of O 2 Ϫ by Ang II. Moreover, infusion of this novel cell-permeant NAD(P)H oxidase inhibitor reduced blood pressure elevation and aortic O 2 Ϫ in response to Ang II in vivo. The lack of any noticeable adverse reaction in these mice, as well as the fact that scramb-tat at the same concentration had no effect, indicated that the dose we used was safe in vivo. These data are consistent with the hypothesis that induction of vascular NAD phox has been reported to be an essential component in the vasculature, since mice lacking this subunit showed lower levels of O 2 Ϫ compared with wildtype mice. 41 These findings provided a further rationale for development of competitive inhibitors of gp91 phox and p47 phox interaction. In these studies, we developed a means to inhibit ongoing assembly of NAD(P)H oxidase in response to Ang II by interfering with the interaction of these two critical components. When cytosolic p47 phox is activated in neutrophils, it is phosphorylated, which enhances its interaction with p67 phox . This complex then translocates to the inner surface of the plasma membrane where p47
phox interacts with gp91 phox , which is necessary for full activation of the enzyme. 28 Evidence for this translocation has been reported for endothelial cells and smooth muscle cells. 22 Thus gp91ds-tat was designed to inhibit the interaction of gp91 phox and p47
phox . Other studies have suggested the use of a cell-permeant antimicrobial peptide called PR-39 to inhibit NAD(P)H oxidase assembly, but its intracellular target is not clear and its antimicrobial properties raise some concern. 42 Apocynin is described as an effective inhibitor of phagocyte oxidase assembly that has recently been shown to inhibit endothelial cell O 2
Ϫ
. 22 However, the activity of apocynin reportedly requires its conversion by myeloperoxidase, 43 which is only present in myeloid cells. 44 Thus, it is unclear why apocynin is active in endothelial cells. Perhaps, analogous peroxidases subserve such activation in the endothelium. Incidentally, we have been unable to show that apocynin can attenuate O 2 Ϫ generation in rat aortic smooth muscle cells and fibroblasts (authors' unpublished observations, 2001).
The peptide inhibitor sequence we chose (gp91ds) was found to be most potent compared with other related sequences in neutrophil cell-free assays, with an IC 50 of 1 to 3 mol/L and an ability to block 80% of O 2 Ϫ production. 28,29 Although we have not obtained full dose-response curves for gp91ds-tat in vascular tissue, the concentration we used in our in vitro studies is consistent with the previously reported efficacy of gp91ds alone. 29 Moreover, the ineffectiveness of tat or scramb-tat precludes a nonspecific effect of cell membrane transmigration on O 2 Ϫ measurements. We also tested the hypothesis that gp91ds-tat could directly scavenge O 2 Ϫ or inhibit other enzymes. For this, we examined its effect on KO 2 and XO/hypoxanthinegenerated O 2 Ϫ in vitro. In both cases, gp91ds-tat failed to alter O 2 Ϫ steady-state levels, indicating that it is not an O 2 Ϫ scavenger or an inhibitor of XO.
gp91ds-tat completely inhibited Ang II-induced aortic O 2 Ϫ both in vitro and in vivo as measured by two methods of O 2 Ϫ detection. Using chemiluminescence, we found that the Ang II-induced increase in whole aortic O 2 Ϫ levels was returned to control levels by gp91ds-tat. We also showed that Ang IIinduced NAD(P)H oxidase activity in fibroblasts was reversed by gp91ds-tat confirming the ability of the peptide to specifically inhibit this oxidase. Ang II has been reported to significantly increase gp91 phox 12 and nox1, a shorter homologue of gp91 phox involved in smooth muscle oxidase activity, 25 and antisense to nox1 can attenuate such an increase. 31 Thus, we cannot exclude the possibility that gp91ds-tat is inhibiting oxidase isoforms containing both these homologues. Indeed, we showed that Ang II-induced HE staining was reduced by gp91ds-tat in all three vascular layers. Not only do these findings with HE confirm our results with chemiluminescence, but they also suggest that gp91ds-tat can inhibit the various vascular oxidase isoforms. When we searched the rat nox1 sequence LALIGN server (available at http://www.ch.embnet.org/software/LALIGN_form.html), we found a region of conserved homology with our inhibitory peptide (amino acids 86 to 94). 25 Moreover, renox (nox4), first reported in the kidney 26 and now shown to be expressed in smooth muscle cells, 31 has substantial homology with the gp91ds peptide sequence (amino acids 91 to 98). However, Lassègue et al 31 have shown that nox4 levels are decreased in response to Ang II, and thus it is unlikely that nox4 accounts for the increase in medial HE staining. The fact that HE staining was inhibited by gp91ds-tat in all vascular layers is consistent with its ability to inhibit at least 2 of the NAD(P)H oxidase isoforms (gp91 phox and nox1). Future studies will be necessary to directly examine the ability of this peptide to inhibit assembly of nox1 and nox4 with p47 phox . gp91ds has been shown to effectively inhibit neutrophil oxidase assembly in a cell-free assay. 28, 29 However, upon testing the effect of these compounds on O 2 Ϫ production by intact human neutrophils, we found lower inhibitory activity; that is, concentrations of gp91ds-tat up to 100 mol/L were only capable of decreasing O 2 Ϫ by 35%. It is noteworthy that 50 mol/L gp91ds-tat completely inhibited Ang II-induced aortic O 2 Ϫ but was only capable of inhibiting neutrophil activity by 24%. It is not clear why gp91ds-tat was more effective in inhibiting vascular cell NAD(P)H oxidase in these studies. However, it is evident from our studies 39 and others 45 that vascular NAD(P)H oxidase is regulated differently from phagocyte NAD(P)H oxidase, which may account for the difference in efficacy. Second, the higher concentration of cytosolic oxidase proteins and granule stores of flavocytochrome b also provides neutrophils with a ready supply of oxidase proteins to replenish inactive oxidase complexes. 28, 46 Currently, there is no evidence for similar internal stores of NAD(P)H oxidase in vascular cells. Perhaps most importantly, degradation of peptides on the neutrophil surface by exoproteases is likely to prevent them from reaching the assembling NAD(P)H oxidase complex, necessitating the addition of higher peptide concentrations to achieve similar levels of inhibitory activity. 47, 48 Finally, although a one amino acid difference in the gp91ds of human neutrophils could explain a lower efficacy of the mouse gp91ds, it is unlikely to explain such a marked reduction in activity. This difference in the efficacy of gp91ds-tat in the vasculature versus neutrophils may provide a therapeutic advantage, allowing inhibition of vascular O 2 Ϫ production while preserving normal neutrophil antimicrobial function.
We previously showed that infusion of Ang II into mice caused a significant increase in NAD(P)H oxidase components and O 2 Ϫ , mediated through the angiotensin type 1 (AT 1 ) receptor and accompanied by SBP elevation. 12 This was consistent with a previous report by Laursen et al 11 in rats showing that Ang IIbut not norepinephrine-dependent hypertension increases vascular O 2 Ϫ production. In their model, liposome-encapsulated SOD was capable of partially attenuating the increase in blood pressure. 11 Likewise, our present data show a partial attenuation of Ang II-induced hypertension by gp91ds-tat. Since gp91ds-tat only partially attenuated the development of hypertension in the Ang II-treated mice, but completely reduced Ang II-increased O 2 Ϫ in the aorta, a partial contribution of O 2 Ϫ from NAD(P)H oxidase in the development of hypertension is suggested. A partial contribution by this enzyme or class of enzymes is not surprising, as the hypertensive effects of Ang II are complex, 49 and much of the increase in blood pressure is likely related to direct activation of AT 1 receptors, excitation/contraction, 49 and a variety of other central and peripheral effects. 50 Indeed, Laursen et al 11 showed that after 5 days of infusion, Ang II (0.75 mg · kg Ϫ1 · d
Ϫ1
) impaired aortic endothelium-dependent relaxation ex vivo, which was restored by cotreatment with liposomal SOD; however, it did not completely normalize blood pressure. Moreover, whereas NAD(P)H oxidase is a major source of O 2 Ϫ in the aorta, 14 these studies have not been addressed in resistance vessels to our knowledge. It is plausible that the degree of O 2 Ϫ inhibition in resistance vessels will more accurately reflect the blood pressure-lowering effect of gp91ds-tat. These and other studies will be necessary to determine whether greater reductions in blood pressure might be achieved with higher concentrations of gp91ds-tat.
In summary, these data provide evidence for the involvement of gp91 phox or its homologues in vascular O 2 Ϫ production and for ongoing assembly with p47 phox , contributing to vascular O 2 Ϫ production and blood pressure elevation. Moreover, inhibition of this NAD(P)H oxidase is likely to promote vascular protection in a variety of disease states in which this enzyme is activated and implicated in vascular remodeling, such as restenosis and atherosclerosis. 51, 52 This novel inhibitor could avoid compensatory and developmental issues associated with oxidase deletion and permit inhibition to be targeted to various cell types.
